CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273181608
- Phone
- 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-24 | Baldry Mark Chief Commercial Officer | Sale | −29,159 | $0.45 | $13K | 94,123 |
| 2025-01-24 | DiBiase Mary Chief Operating Officer | Sale | −22,258 | $0.45 | $10K | 490,980 |
| 2025-01-24 | Arbet-Engels Christophe Chief Medical Officer | Sale | −11,624 | $0.45 | $5K | 14,207 |
| 2025-01-23 | Ragan Paula President and CEO | Grant or award | +169,940 | 1,163,859 | ||
| 2025-01-23 | Mostafa Adam S. Chief Financial Officer | Grant or award | +74,773 | 74,773 | ||
| 2025-01-23 | Baldry Mark Chief Commercial Officer | Grant or award | +74,773 | 123,282 | ||
| 2025-01-23 | DiBiase Mary Chief Operating Officer | Grant or award | +61,178 | 513,238 | ||
| 2025-01-23 | Arbet-Engels Christophe Chief Medical Officer | Grant or award | +25,831 | 25,831 | ||
| 2024-11-15 | Baldry Mark Chief Commercial Officer | Purchase | +13,404 | $0.34 | $5K | 129,173 |
| 2024-11-15 | Ragan Paula President and CEO | Sale | −31,897 | $0.39 | $13K | 993,919 |
| 2024-10-15 | Ragan Paula President and CEO | Sale | −31,897 | $0.56 | $18K | 1,025,816 |
| 2024-10-07 | Mostafa Adam S. Chief Financial Officer | Sale | −230,645 | $0.55 | $127K | 0 |
| 2024-10-07 | Baldry Mark Chief Commercial Officer | Sale | −11,127 | $0.58 | $7K | 48,509 |
| 2024-10-07 | Ragan Paula President and CEO | Sale | −239,436 | $0.55 | $132K | 1,057,713 |
| 2024-10-07 | DiBiase Mary Chief Operating Officer | Sale | −67,695 | $0.57 | $38K | 452,060 |
| 2024-10-07 | Taveras Arthur Chief Scientific Officer | Sale | −76,920 | $0.56 | $43K | 388,026 |
| 2024-10-04 | Mostafa Adam S. Chief Financial Officer | Grant or award | +230,645 | 230,645 | ||
| 2024-10-04 | Baldry Mark Chief Commercial Officer | Grant or award | +34,946 | 59,636 | ||
| 2024-10-04 | Ragan Paula President and CEO | Grant or award | +532,081 | 1,297,149 | ||
| 2024-10-04 | DiBiase Mary Chief Operating Officer | Grant or award | +230,645 | 519,755 |
Page 3 of 6 · 120 trades